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Case report of Strongyloides stercoralis hyperinfection 
– a lesson for the immunocompromised patients` treatment
Prikaz bolesnika sa Strongyloides stercoralis hiperinfekcijom 
– lekcija za liječenje imunokompromitiranog bolesnika
Abstract
Strongyloides stercoralis is an intestinal nematode that causes 
chronic gastrointestinal infection. In immunosuppressed patients 
this persistent disease can lead to disseminated disease and/or 
hyperinfection that are life threatening conditions. We present 
a fatal case of S. stercoralis hyperinfection and the appropriate 
treatment for immunosuppressed patients is discussed.
Sažetak
Strongyloides stercoralis je crijevna nematoda koja uzrokuje 
kroničnu gastrointestinalnu infekciju. Kod imunokompromiti-
ranih bolesnika ova perzistentna bolest može dovesti do dise-
minirane bolesti i/ili hiperinfekcije koje su životno ugrožavaju-
će. Prikazujemo slučaj hiperinfekcije S. stercoralis sa smrtnim 
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Strongyloides stercoralis is a common intestinal nematode 
and it is estimated that it affects up to 100 million people 
worldwide. It is endemic in Africa and Asia, as well as in 
Central and South America. Human infection occurs when 
filariform larvae penetrate intact skin. The life cycle of S. 
stercoralis can be divided in two parts: part where it is 
outside a host as a free living rhabditiform larvae and a 
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BID was started. In the next 24 hours his general condition 
further deteriorated. He was intubated and shifted to the 
ICU where ivermectin 200 mg/kg was added. His condi-
tion stabilized however during the next two days his blood 
pressure decreased. He had to be on inotropic support and 
laboratory results showed multiorgan failure. The patient 
died on the seventh day of his hospitalisation.
Discussion
 The majority of infected people have chronic but asymp-
tomatic gastrointestinal tract infection. S. stercoralis has 
the unique ability to complete its life cycle in the human 
host causing the autoinfection that can lead to persistent 
infection for decades. If the patient has impaired cell-me-
diated immunity (e.g, steroid or other immunosuppressant 
treatment, transplant patients, patients infected with human 
T-cell lymphotrophic virus type 1) normal S. stercoralis 
life-cycle is accelerated leading to excessive worm burden 
within the usual migration route (skin, gut, lungs). This 
condition is labeled as hyperinfection syndrome (HIS). If 
larvae are spread even to other organs (liver, brain, heart, 
urinary tract) the condition is labeled as disseminated in-
fection syndrome (DIS). Clinical presentation of HIS and 
DIS is similar to usual strongyloidiasis symptoms includ-
ing nausea, vomiting, diarrhea, weight loss, abdominal 
pain, cough, fever, dyspnea and gastrointestinal bleeding. 
However, because of massive infection and dissemination, 
HIS and DIS patients can have catastrophic presentation 
like shock, disseminated intravascular coagulation, men-
ingitis, renal and/or respiratory failure [2].
 It seems that in the last years the global prevalence of 
S. stercoralis infection is increasing, especially in previ-
ously known endemic areas where the poor sanitary meas-
ures, poor personal hygiene, as well as the insufficient 
drinking water supply are the main reasons for the infec-
tion rate increase. At the same time there are many isolat-
ed S. stercoralis infection cases occurring in non-endemic 
areas mostly associated with patients with immunosup-
pressive diseases, corticosteroid therapy, organ transplant 
recipients, hematological malignancies or other debili-
tating conditions [1]. Data about the S. stercoralis prev-
alence in non-endemic areas are scarce and the increasing 
number of high-risk patients emphasizes the importance 
of appropriate diagnosis and treatment of this potentially 
fatal infection. The actual human prevalence in Croatia is 
not known although the Strongyloides spp was detected in 
0,5% of Croatian wild wolves faecal samples [3].
 The microbiological diagnosis of strongyloidiasis can 
be challenging. Initially eosinophilia and/or increased to-
tal-IgE may raise suspicion of Strongyloides but may be 
absent in immunocompromised patients. It is based on 
either finding the larvae in stool samples or on demon-
strating specific antibodies to S. stercoralis in blood. Fecal 
microscopy can detect the first stage larvae whereas the 
eggs or adults are not common to see. Microscopy has low 
parasitic part inside a host as an infective filariform lar-
vae. During the free living cycle rhabditiform larvae trans-
forms into filariform ones which can actively penetrate the 
human skin reaching venous circulation, right heart and fi-
nally lungs. From alveoli larvae migrate up the pulmonary 
tree reaching trachea and larynx from where they come to 
pharynx. Reaching the pharynx they are swallowed and 
in the small bowel the larvae maturate into adults. They 
embed into the small bowel mucosa and start producing 
eggs by parthenogenesis. Within the intestinal lumen the 
eggs hatch into non-infective rhabditiform larvae that are 
excreted along with the stool reaching the soil. Sometimes 
rhabditiform larvae transform into filariform larvae even 
inside the host’s small bowel. The filariform larvae pene-
trate intestinal mucosa reaching the blood stream or they 
actively penetrate perianal skin causing autoinfection [1]. 
In people with impaired cellular immunity this persistent 
infection can lead to disseminated disease and/or hyperin-
fection that are life threatening conditions. In this article 
we present a fatal case of S. stercoralis hyperinfection in a 
patient with plasma cell myeloma.
Case presentation
 A 63-year-old male with plasma cell myeloma, pre-
sented to our Emergency Room with a four days histo-
ry of fever, cough, abdominal pain and diarrhea up to 
three times a day. The last 19 months he was treated with 
lenalidomide, dexamethasone and zoledronic acid for 
the myeloma. At the admission he was febrile 38°C and 
chest auscultation showed bilateral crepitation while the 
rest findings was unremarkable. Initial laboratory tests 
showed that his white blood cells were 6 x 109/L with 
40% neutrophils, 31% lymphocytes, 27% monocytes and 
2% eosinophils while CRP was 103 mg/L. Chest x-ray 
at the admission showed bilateral infiltrations so the em-
pirical treatment with piperacillin with tazobactam 4,5 g 
TID, levofloxacin 500 mg OD and oseltamivir 75 mg OD 
was started. After the admission he started to desaturate 
so he was put on Bilevel Positive Airway Pressure (Bi-
PAP) mode of noninvasive ventilation. Chest CT showed 
bilateral upper and mid zones of peri bronchial and ground 
glass opacities while the abdominal CT revealed features 
of colitis in the descending and sigmoid colon and to less-
er extent of similar changes in the rectum. Bronchoscopy 
was done and bronchoalveolar lavage (BAL) cytology 
showed mixture of alveolar macrophages, bronchial epi-
thelial and squamous cells. Many roundworm organisms 
with notched tails were noticed in BAL and their morphol-
ogy was suggestive of Strongyloides nematodes (Figure 
1). Blood, urine and BAL cultures were negative, cyto-
megalovirus (CMV) polymerase chain reaction (PCR) in 
blood was negative, legionella and pneumococcus antigen 
were negative in urine and acid-fast bacilli (AFB) smear 
and PCR as well as pneumocystis pneumonia (PCP) PCR 
were negative in BAL. S. stercoralis was found in the 
stool sample and the treatment with albendazole 400 mg 
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further stool examination was done. The HIS that our pa-
tient presented with four months later confirms that 7 days 
of albendazole was not the adequate treatment as it didn’t 
eliminate the possibility of autoinfection. In high-risk pa-
tients it is imperative to repeat diagnostic studies (stool, 
duodenal fluid, endoscopy) in order to confirm or rule out 
the parasite eradication [2]. Eosinophilia is not a reliable 
parameter for the treatment surveillance but can be used in 
combination with serial antibody titers [6].
Conclusions
 In immunocompetent people S. stercoralis often caus-
es chronic and asymptomatic infection that can be lifelong. 
In patients that are immunosuppressed, especially in those 
who are treated with steroids, the number of parasites can 
substantially increase leading to potentially fatal hyper or 
disseminated infection. To prevent these serious seque-
lae all chronically infected patients should be diagnosed 
and treated. This suggestion is obvious for Strongyloides 
endemic areas but as it is little known about the stron-
gyloidiasis prevalence in non-endemic areas, it should be 
applied in non-endemic areas too. In non-endemic areas 
the prevalence studies should be done in order to assess 
the risk of S. stercoralis infection. Also it would be advis-
able to include S. stercoralis screening in the pretreatment 
workup for the high risk patients that are prepared for im-
munosuppressive treatment.
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sensitivity as larvae are shed sporadically and in numbers 
which depends on the stage and severity of the infection. 
In order to increase the sensitivity of microscopy it is rec-
ommended that few stool specimens collected over sev-
eral consecutive days are examined. Coproculture is an 
additional stool examination method which aims to detect 
larvae in freshly passed stool samples.
 Detection of anti-Strongyloides antibodies in blood 
samples should be done as a screening test or as an ad-
ditional test for making diagnosis. Together with the eo-
sinophil count it can be used to monitor the treatment. 
The drop in antibody levels is variable. Usually it could 
be seen only after 6 months of the effective treatment. 
The sensitivity of commercially available EIA tests using 
Strongyloides filariform antigen is estimated to be around 
90 percent but in the case of profound immunosuppression 
sensitivity can be lower. At the same time, cross reactions 
with other nematodes can’t always be excluded [4]. In cas-
es when serology is positive it is suggested to confirm or 
rule out the cross reaction using direct microscopic or cul-
ture diagnostics. Molecular test for diagnostic have been 
developed recently but their use has not been routine yet.
 The objective of strongyloidiasis management is to 
treat symptomatic patients, to eradicate the parasite from 
the host thus eliminating the possibility of autoinfection, 
and to prevent possible complications in asymptomatic 
patients. Today, the first-line treatment for strongyloidiasis 
is ivermectin that eradicates the parasite in approximately 
80% patients. It is highly effective as it targets both adults 
and larvae. For uncomplicated S. stercoralis infection oral 
ivermectin is given 200 mg/day for two days. Alternative 
treatment is albendazole 400 mg twice a day for 7 days 
but it is shown to be less effective most probably because 
it primarily targets adult worms. HIS/DIS should be con-
sidered as medical emergencies so the treatment should 
be started as soon as this diagnosis is considered. In these 
situations ivermectin 200 mg/day should be given for at 
least two weeks or until the parasite has not been detected 
in the stool for the full two weeks. There are some reports 
about improved efficacy of the ivermectin and albenda-
zole combination but so far there are no randomized trials 
confirming this conclusion [5]. The additional manage-
ment that could benefit the patients is the reduction of im-
munosuppressive treatment if this would be possible due 
to patient’s underlying condition.
 After our patient’s death, a review of his medical record 
showed that four months prior this admission he com-
plained on abdominal pain and diarrhea. At the same time 
eosinophilia of 14-27% in his peripheral blood was detect-
ed and S. stercoralis was found in the stool. He was treated 
as an outpatient with albendazole 400 mg twice a day for 7 
days advising him to take medications with fatty food. At 
the same time the dexamethasone dose was reduced from 
40 to 20 mg daily. After the treatment his bowel movement 
normalized, he didn’t complain on the abdominal pain and 
eosinophilia was not present any more. Unfortunately no 
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Figure 1. Strongyloides nematode in bronchoalveolar lavage
